Objective: Relationship between pretreatment uptake of 18 F-fluoro-2-deoxy-D-glucose and local control after stereotactic body radiotherapy in stage I non-small-cell lung cancer was examined. Methods: Between June 2006 and June 2009, 90 clinically diagnosed stage I primary lung cancer in 86 patients were treated with stereotactic body radiotherapy in Shikoku Cancer Center. Among these, 51 tumors in 51 patients were evaluated by positron emission tomography using 18 F-fluoro-2-deoxy-D-glucose before treatment. Twenty-six tumors of histopathologically confirmed non-small-cell lung cancer were reviewed in this study. Tumors were divided into two groups by the threshold maximum standardized uptake value of 5.0 (high-uptake tumors, 9; low-uptake tumors, 17). One tumor with low uptake was pure ground-glass opacity. Typically, 48 Gy in four fractions was given at the isocenter. Results: Follow-up time was 4 -44 months (median, 21 months). Local failure-free rates at 15 months of the high-uptake group and the low-uptake group were 40% and 93% for all tumors (P ¼ 0.0001), 0% and 91% for tumors 3 cm or less (P ¼ 0.0004), 50% and 100% for tumors larger than 3 cm, and 40% and 89% for the mainly solid tumors (P ¼ 0.0010). There were no statistically significant differences of local failure-free rates according to age, sex and tumor size (P ¼ 0.4804, P ¼ 0.4170 and P ¼ 0.3638, respectively). Conclusions: High uptake of 18 F-fluoro-2-deoxy-D-glucose in a primary tumor was the significant unfavorable factor for local control after stereotactic body radiotherapy in stage I non-small-cell lung cancer.
INTRODUCTION
Stereotactic body radiotherapy (SBRT) is effective for local control of early stage non-small-cell lung cancer; however, local failure occurs in around 10% of tumors after SBRT in stage I non-small-cell lung cancer (1 -4) .
Currently, there is an increasing interest in the role of positron emission tomography (PET) using 18 F-fluoro-2-deoxy-D-glucose (FDG) beyond staging, such as the evaluation of biological characteristics of the tumor and prediction of prognosis in the context of treatment stratification and the early assessment of tumor response to therapy. The prognostic value of pretreatment PET using FDG has been evaluated in patients who had stages I -III non-small-cell lung cancer treated with surgery and/or conventional radiotherapy (5 -18) . Although the data are varied, patients with primary tumors showing high FDG uptake tend to have a more aggressive clinical course than those with low FDG uptake. A recent meta-analysis concluded that metabolic activity of the primary tumor, as determined by the maximum standardized uptake value (SUVmax) on FDG-PET, is a prognostic factor in patients with non-small-cell lung cancer (19) .
Concerning the stage I non-small-cell lung cancer treated with SBRT, the relationship between FDG uptake of the primary tumors and treatment results has not been well examined. In the present study, the relationship between pretreatment FDG uptake of the primary tumors and local control after SBRT for stage I primary lung cancer was examined.
PATIENTS AND METHODS
Between June 2006 and June 2009, 90 clinically diagnosed stage I primary lung cancer in 86 patients were treated with SBRT in Shikoku Cancer Center. Of these 90 clinically diagnosed tumors, 51 tumors in 51 patients were examined by PET/computed tomography using FDG (FDG-PET/CT) before SBRT. FDG-PET/CT was often performed for differential diagnosis of a lung tumor that had been highly suspected of lung cancer on serial CT but of which histopathological identification had not been able to be obtained. Therefore, the proportion of histopathologically confirmed tumors was comparatively low in tumors examined by FDG-PET/CT. Of the 51 tumors examined by FDG-PET/CT, 26 tumors were histopathologically confirmed as non-small-cell lung cancer. These 26 tumors in 26 patients were reviewed in the present study.
The median of pretreatment SUVmax was 2.6 (range, 0.8 -15.9). The 26 tumors were divided into two groups by the pretreatment SUVmax. We determined the SUVmax of 5.0 as the cutoff point for division between the high SUVmax group and the low SUVmax group in this study. The total number of tumors was 9 for high SUVmax group (SUVmax .5.0) and 17 for the low SUVmax group (SUVmax ,5.0). The SUVmax of the high SUVmax group ranged from 5.4 to 15.9 (median: 7.7), and the SUVmax of the low SUVmax group ranged from 0.8 to 4.7 (median: 2.3).
One tumor less than 3 cm in greatest dimension was diagnosed as a T2 tumor because of suspicion of invasion to the visceral pleura (SUVmax ¼ 1.2). Characteristics of tumors are shown in Table 1 .
FDG-PET/CT PROCEDURE
In PET/CT study, PET and CT images (both 5 mm slice) were obtained 90 min after injection of 3 MBq/kg 18 F-FDG.
SBRT PROCEDURE
For SBRT, micro-multileaf collimator system 'BrainLAB m3' (BrainLAB, Germany) was used. Immobilization body frame (BodyFIX, Medical Intelligence, Germany) was used for patient fixation during CT scanning for treatment planning and SBRT. Three-dimensional RT planning was performed using a treatment-planning machine (BrainSCAN, BrainLAB, Germany). The software of BrainSCAN adopted the pencil beam method as calculation algorithm. The pencil beam method did not perform heterogeneity correction.
Internal target volumes were defined as visible lesions on slow CT images (slice thickness 2 mm; 4 s/slice) acquired under shallow breathing using an abdominal compression belt. In determination of planning target volumes, a margin of 5 mm was added to the contours of internal target volumes in principle. The typical leaf margin of the micromultileaf collimator was 3 mm in our institution. In principle, 48 Gy in four fractions was delivered to the isocenter by 8 -11 non-coplanar static 4 MV photon beams in SBRT. Four of eight tumors larger than 3 cm were given doses 54 -60 Gy at the isocenter (60 Gy in five fractions, 3; 54 Gy in four fractions, 1). Remaining four tumors larger than 3 cm were given 48 Gy in four fractions. All of the tumors 3 cm or less were given 48 Gy in four fractions at the isocenter. In principle, leaf margins were arranged that 90-95% isodose-line covers the planning target volumes.
EVALUATION
In principle, follow-up CT was performed every 2 -3 months for 2 years after SBRT. It is often difficult to distinguish tumor remnant or regrowth from radiation-induced changes such as consolidation or pulmonary fibrosis. Such cases were Time to local failure was calculated from the first day of SBRT to the day when local failure was confirmed. The local failure-free rates were calculated by Kaplan -Meier method, and differences of local failure-free rates were evaluated by log-rank test. Assessed factors in the present study were age (,80 vs. 80), sex, SUVmax (,5.0 vs. .5.0) and tumor size (3 cm vs. .3 cm).
RESULTS

FOLLOW-UP TIME
Follow-up time was 4 -44 months (median, 21 months).
Follow-up time of the high SUVmax group and the low SUVmax group were 4 -34 months (median, 13 months) and 9 -44 months (median, 23 months), respectively. Follow-up time of locally controlled tumors was 4 -44 months (median, 21 months).
TREATMENT RESULTS
The 1 and 2 year local failure-free rates of all tumors were 88% and 73%, respectively. Time to local failure was 4 -17 months (median, 10.5 months).
Local failure-free rates at 15 months of the high-uptake group and the low-uptake group were 40% and 93% for all tumors (P ¼ 0.0001), 0% and 91% for tumors 3 cm or less (P ¼ 0.0004), 50% and 100% for tumors larger than 3 cm (P value could not be evaluated because local failure did not occur in one group during follow-up time), and 40% and 89% for the mainly solid tumors (P ¼ 0.0010) (Figs 1 -4 ). There were no statistically significant differences of local failure-free rates according to age (,80 vs. .80 years), sex and tumor size (3 vs. .3 cm) on log-rank test (P ¼ 0.4804, P ¼ 0.4170 and P ¼ 0.3638, respectively) ( Table 2) . Details of local-failure cases are shown in Table 3 .
DISCUSSION
Although TNM staging system provides prognostic information, it provides an incomplete biologic profile of non-small-cell lung cancer. Stage I non-small-cell lung cancer potentially includes biologically aggressive tumors and biologically indolent tumors. Because FDG uptake is a potential indicator for biological aggressiveness of cancer, we examined the relationship between the FDG uptake of the primary tumors and local control after SBRT. In the present study, we divided the patients into the high SUVmax tumors and the low SUVmax tumors with the cutoff point of SUVmax of 5.0. In previous studies that evaluated the relationship between SUVmax and prognosis of lung cancer, the adopted cutoff points of the SUVmax ranged from 3.3 to 20 (5 -12,14,15,17,18) . These studies showed that a broad range of the SUVmax can be used as the cutoff point for prediction of prognoses. This implies that the relation between the SUVmax and prognosis could be a gradual one rather than based on a threshold. It seems reasonable to hypothesize that there is no true cutoff point but a transition zone, within which the prognosis gradually worsens. In the present study, all of the low SUVmax tumors were given 48 -50 Gy, while four of nine high SUVmax tumors were given higher doses (54 -60 Gy). Nonetheless, the local failure-free rate of all of the high SUVmax tumors On the other hand, there was no statistically significant difference of the local failure-free rates between tumors 3 cm or less and tumors larger than 3 cm. Because FDG uptake is affected not only by tumor size but also by the metabolic activity of the tumor, SUVmax of the tumor seemed to be a more significant prognostic factor for local control after SBRT compared with tumor size in stage I non-small-cell lung cancer.
Although there were several limitations including short follow-up, limited sample size and its retrospective nature to our study, strong relationship between a SUVmax of a tumor and the local failure-free rate after SBRT for stage I non-small-cell lung cancer was found.
Based on our results, not only T-stage but also degree of FDG uptake of the primary tumors should be considered in determination of the total doses and fraction size of SBRT. Higher total doses and/or larger fraction size may be necessary for the high SUVmax tumors to improve local control rates after SBRT.
CONCLUSION
In stage I non-small-cell lung cancer treated with SBRT, pretreatment high SUVmax of a primary tumor on FDG-PET was associated with poor local control. Because of small sample size, comparatively short follow-up and retrospective nature of our study, further studies are necessary. Mainly GGO (n ¼ 6) 100 100 LFFR, local failure-free rates; SUVmax, maximum standardized uptake value; SqCC, squamous cell carcinoma; GGO, ground glass opacity.
a P value could not be evaluated because local failure did not occur in one group during follow-up time. 546 FDG uptake and local control of SBRT in lung cancer
